Breakthrough Pain
Information
- Disease name
- Breakthrough Pain
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02278601 | Active, not recruiting | Phase 3 | Comparison of Regimens MPIB, CIPCEA, PCEA | January 28, 2015 | December 31, 2025 |
| NCT00236145 | Completed | Phase 3 | Evaluate the Efficacy and Safety of ACTIQ in Patients With Cancer and Breakthrough Pain | June 2004 | |
| NCT00402350 | Completed | Phase 1 | Staccato Fentanyl Single and Multidose PK | April 2006 | November 2006 |
| NCT00236041 | Completed | Phase 2 | Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP) | April 2004 | August 2006 |
| NCT02050503 | Completed | Intranasal Transmucosal Fentanyl Pectin for Breakthrough Cancer Pain in Radiation-induced Oropharyngeal Mucositis | December 2012 | June 2014 | |
| NCT02437929 | Completed | Procedural Pain in Palliative Care: Prevalence, Intensity and Treatment | June 2015 | April 2016 | |
| NCT02836379 | Completed | Quality of Life Study Breakthrough Cancer Pain Treated in Radiation Oncology Services With Palliative Intent | July 8, 2016 | February 28, 2018 | |
| NCT02840500 | Completed | Quality of Life Study in Patients With Cancer Breakthrough Pain Treated in Palliative Care Units | June 27, 2016 | March 2018 | |
| NCT02869321 | Completed | Phase 4 | Analgesic Efficacy of Transmucosal Fentanyl for Breakthrough Pain Caused by Interventional Gastrostomy | May 2015 | May 2018 |
| NCT02886286 | Completed | Phase 4 | Patient Controlled Intrathecal Analgesia With Bupivacaine for Chronic Low Back Pain | May 2016 | December 2017 |
| NCT03435120 | Completed | Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM) | December 21, 2017 | February 14, 2020 | |
| NCT00994760 | Completed | Efficacy and Tolerability of Intranasal Fentanyl Spray for the Treatment of Breakthrough Pain in Cancer Patients Older Than 18 Years | September 2009 | November 2010 | |
| NCT01842893 | Completed | Phase 3 | Efficacy and Safety of Fentanyl ETHYPHARM for Breakthrough Pain in Opioid-treated Patients With Cancer | November 2011 | July 2012 |
| NCT04011150 | Recruiting | Phase 3 | Development of Variable Volume Automated Mandatory Boluses for Patient-controlled Epidural Analgesia During Labour | August 11, 2020 | August 31, 2025 |
| NCT05200806 | Recruiting | Phase 4 | A Prospective Pilot Study of a Non-Narcotic Post-Operative Course After Colectomy | February 7, 2022 | October 2024 |
| NCT01901718 | Terminated | An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys™ Spray. | April 2013 | January 2014 | |
| NCT00842829 | Terminated | Phase 4 | Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients | January 2009 | May 2011 |
| NCT00387010 | Terminated | Phase 3 | Open-Label Study to Evaluate the Effect of Treatment With Fentanyl Buccal Tablets on Pain Anxiety Symptoms When Used for the Management of Breakthrough Pain | December 2006 | October 2007 |
| NCT05053308 | Withdrawn | N/A | Proportional Dose of Sublingual Fentanyl Tablet Based on Daily Opioid Requirement | December 1, 2022 | December 31, 2023 |
| NCT03809455 | Withdrawn | Phase 2 | Effectiveness and Tolerance of Fentanyl Citrate in Painful Pain Induced During Diagnostic or Therapeutic Examinations in Cancer Patients | February 1, 2020 | February 1, 2023 |
- MeSH unique ID (MeSH (Medical Subject Headings))
- D059390